title: A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study.
abstract: OBJECTIVE
  The goal of this study was to determine if B-type natriuretic peptide (BNP) levels predict outcomes of patients admitted with decompensated heart failure.
  
  
  BACKGROUND
  Treatment of decompensated congestive heart failure (CHF) has often been based on titration of drugs to relieve patient's symptoms, a case that could be made for attempting to also treat neurohormonal abnormalities. Because BNP reflects both elevated left ventricular pressure as well as neurohormonal modulation, we hypothesized that BNP might be useful in assessing outcomes in patients admitted with decompensated CHF.
  
  
  METHODS
  We followed 72 patients admitted with decompensated New York Heart Association class III to IV CHF, measuring daily BNP levels. We then determined the association between initial BNP measurement and the predischarge or premoribund BNP measurement and subsequent adverse outcomes (death and 30-day readmission).
  
  
  RESULTS
  Of the 72 patients admitted with decompensated CHF, 22 end points occurred (death: n = 13, readmission: n = 9). In these patients, BNP levels increased during hospitalization (mean increase, 233 pg/ml, p < 0.001). In patients without end points, BNP decreased (mean decrease 215 pg/ml). Univariate analysis revealed that the last measured BNP was strongly associated with the combined end point. In patients surviving hospitalization, BNP discharge concentrations were strong predictors of subsequent readmission (area under the receiver operator curve of 0.73).
  
  
  CONCLUSIONS
  In patients admitted with decompensated CHF, changes in BNP levels during treatment are strong predictors for mortality and early readmission. The results suggest that BNP levels might be used successfully to guide treatment of patients admitted for decompensated CHF.
authors.affiliation: Division of Cardiology, Veteran's Affairs Medical Center, San Diego, California, USA.
authors.forename: V
authors.initials: V
authors.lastname: Cheng
authors.forename: R
authors.initials: R
authors.lastname: Kazanagra
authors.forename: A
authors.initials: A
authors.lastname: Garcia
authors.forename: L
authors.initials: L
authors.lastname: Lenert
authors.forename: P
authors.initials: P
authors.lastname: Krishnaswamy
authors.forename: N
authors.initials: N
authors.lastname: Gardetto
authors.forename: P
authors.initials: P
authors.lastname: Clopton
authors.forename: A
authors.initials: A
authors.lastname: Maisel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D009320:Atrial Natriuretic Factor / Q000097:blood*; D002316:Cardiotonic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004232:Diuretics / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain; D010343:Patient Admission; D010865:Pilot Projects; D019095:Point-of-Care Systems; D011237:Predictive Value of Tests; D011379:Prognosis; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D002316:Cardiotonic Agents; D004232:Diuretics; D014665:Vasodilator Agents; D020097:Natriuretic Peptide, Brain; D009320:Atrial Natriuretic Factor